Myovant Accepts Higher Sumitovant Offer In Deal That Values It At $2.9bn

Women’s Health, Prostate Cancer Assets To Get A Boost

 
• By Mandy Jackson

Sumitovant, a Sumitomo subsidiary, will pay $27 per share for the 48% of Myovant shares it does not already own, for a deal value of $1.7bn, up from a $22.75-per-share bid in early October.

Big fish eats smaller fish
Sumitomo subsidiary Sumitovant is buying the remaining shares of Myovant • Source: Shutterstock

More from Deals

More from Business